QIAGEN today announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular,…
Arboretum_JDSeptember 17, 2020
NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing high throughput testing solutions to…
Arboretum_JDMay 7, 2020
NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing high throughput testing solutions to…
Arboretum_JDMay 4, 2020
NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing high throughput testing solutions to…
Arboretum_JDMarch 31, 2020
NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing testing solutions to hospital and…
Arboretum_JDMarch 12, 2020
NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today an…
Arboretum_JDOctober 21, 2019
NeuMoDx confirmed today it has received CE-IVD marking on assays to detect and quantify levels…
Arboretum_JDJune 26, 2019
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeuMoDx Molecular, Inc. today announced a…
Arboretum_JDSeptember 17, 2018
NeuMoDx Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today it…
Arboretum_JDAugust 8, 2018
